Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Autolus Forced To Slim Down, But Believes CAR-T Has 'Transformational' Potential

Management Reshuffle And 20% Headcount Cut

Executive Summary

The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.

You may also be interested in...



Lung Cancer Failure Isn't The End For Merck KGaA And GSK's Bintrafusp

Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.

Beam And Verve Benefit From Buzz Around Base-Editing Therapies

Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.

Immunocore Aims For $100m IPO After Immunotherapy Success

The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.

Topics

Related Companies

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel